Martin Shkreli

American entrepreneur and investor best known for founding Turing Pharmaceuticals and for his role in the 2015 Daraprim price controversy. His public work has also included discussion of investing, biotechnology, and AI-assisted drug discovery.

Big Pharma’s Overlooked Drugs Can Become Billion-Dollar Businesses

Martin Shkreli argues that a technology’s technical breakthrough does not make it a sound investment: quantum computing may excel at a narrow set of problems, he says, without offering a viable business case. In a conversation with the Besties, he also describes pharmaceutical opportunity as finding drugs large companies have failed to develop well, while disputing claims that AI will soon transform drug discovery. Looking back on prison, Shkreli says his fixation on being a great trader obscured other paths and relationships that mattered more.

All-In PodcastOct 12, 20268 min read